Studies have shown that the PI3K/AKT-mTOR pathway plays a role in the development of BRAFi resistance by triggering a surrogate survival signaling, leading to resistant BRAFi-treated melanoma cells [57,58]. This evidence concerns the gene AKT1 and melanoma.